Firefly Neuroscience, Inc. (NASDAQ:AIFF) Short Interest Update

Firefly Neuroscience, Inc. (NASDAQ:AIFF) was the target of a significant drop in short interest in March. As of March 31st, there was short interest totaling 1,324,628 shares, a drop of 14.6% from the March 15th total of 1,551,962 shares. Approximately 9.6% of the company’s stock are sold short. Based on an average daily trading volume, of 13,098,562 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC bought a new stake in shares of Firefly Neuroscience during the 4th quarter worth approximately $53,000. Vanguard Group Inc. increased its holdings in Firefly Neuroscience by 393.3% during the third quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock worth $1,464,000 after buying an additional 401,085 shares during the last quarter. Savvy Advisors Inc. acquired a new position in Firefly Neuroscience during the third quarter worth $63,000. Finally, Geode Capital Management LLC raised its position in Firefly Neuroscience by 92.9% during the second quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock worth $341,000 after acquiring an additional 58,067 shares in the last quarter. Institutional investors and hedge funds own 4.96% of the company’s stock.

Firefly Neuroscience Price Performance

Firefly Neuroscience stock opened at $1.76 on Friday. The company has a market cap of $26.03 million, a price-to-earnings ratio of -0.98 and a beta of 0.58. The firm has a 50-day moving average of $1.52 and a 200-day moving average of $1.57. Firefly Neuroscience has a one year low of $0.62 and a one year high of $4.51.

Firefly Neuroscience (NASDAQ:AIFF) last released its earnings results on Tuesday, March 31st. The company reported ($0.16) earnings per share (EPS) for the quarter. Firefly Neuroscience had a negative net margin of 1,740.98% and a negative return on equity of 229.99%. The company had revenue of $0.41 million during the quarter.

Analyst Ratings Changes

AIFF has been the topic of several research reports. Wall Street Zen upgraded Firefly Neuroscience to a “hold” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Firefly Neuroscience in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Firefly Neuroscience Company Profile

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.